- Home
- PXLW vs BCAB Comparison
PXLW vs BCAB Comparison
Compare PXLW & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PXLW
- BCAB
- Stock Information
- Founded
- PXLW 1997
- BCAB 2007
- Country
- PXLW United States
- BCAB United States
- Employees
- PXLW N/A
- BCAB N/A
- Industry
- PXLW Semiconductors
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- PXLW Technology
- BCAB Health Care
- Exchange
- PXLW Nasdaq
- BCAB Nasdaq
- Market Cap
- PXLW 42.0M
- BCAB 40.5M
- IPO Year
- PXLW 2000
- BCAB 2020
- Fundamental
- Price
- PXLW $6.13
- BCAB $0.64
- Analyst Decision
- PXLW Strong Buy
- BCAB Hold
- Analyst Count
- PXLW 3
- BCAB 3
- Target Price
- PXLW $13.67
- BCAB $1.00
- AVG Volume (30 Days)
- PXLW 465.8K
- BCAB 1.2M
- Earning Date
- PXLW 11-11-2025
- BCAB 11-13-2025
- Dividend Yield
- PXLW N/A
- BCAB N/A
- EPS Growth
- PXLW N/A
- BCAB N/A
- EPS
- PXLW N/A
- BCAB N/A
- Revenue
- PXLW $33,961,000.00
- BCAB $11,000,000.00
- Revenue This Year
- PXLW N/A
- BCAB N/A
- Revenue Next Year
- PXLW $23.74
- BCAB N/A
- P/E Ratio
- PXLW N/A
- BCAB N/A
- Revenue Growth
- PXLW N/A
- BCAB N/A
- 52 Week Low
- PXLW $4.67
- BCAB $0.24
- 52 Week High
- PXLW $15.42
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- PXLW 36.39
- BCAB 45.25
- Support Level
- PXLW $6.00
- BCAB $0.61
- Resistance Level
- PXLW $6.47
- BCAB $0.69
- Average True Range (ATR)
- PXLW 0.40
- BCAB 0.08
- MACD
- PXLW -0.12
- BCAB -0.02
- Stochastic Oscillator
- PXLW 9.68
- BCAB 22.95
About PXLW Pixelworks Inc.
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.